RAHWAY, N.J. & CAMBRIDGE, Mass. — In a historic milestone for oncology and mRNA technology, Merck & Co. and Moderna, Inc. announced positive topline results from their Phase 3 INTerpath-001 clinical trial evaluating an experimental personalized cancer vaccine.
The late-stage study demonstrated that combining intismeran autogene (V940 / mRNA-4157)—a custom-tailored mRNA therapy—with Merck’s blockbuster immunotherapy Keytruda (pembrolizumab) significantly delayed cancer recurrence in high-risk melanoma patients compared to Keytruda alone.
Breakthrough INTerpath-001 Trial Results and Key Findings
The INTerpath-001 trial represents the first-ever successful Phase 3 study for an individualized mRNA-based cancer treatment, proving the clinical viability of personalized neoantigen therapies in large-scale clinical settings.
The trial enrolled 1,137 patients with high-risk (stage IIB–IV) cutaneous melanoma whose tumors had been completely removed via surgery.
-
Primary Endpoint Achieved: The combination therapy demonstrated statistically significant and clinically meaningful improvements in Recurrence-Free Survival (RFS), extending the time patients remained cancer-free.
-
Secondary Endpoint Achieved: The combination also met its key secondary endpoint of Distant Metastasis-Free Survival (DMFS), markedly reducing the risk of the cancer spreading to other organs.
-
Safety Profile: No new safety signals were observed during the interim analysis, and adverse events were consistent with previous clinical trials.
-
Stock Market Surge: Following the announcement, shares of Moderna skyrocketed over 60% to 100% in pre-market trading, while Merck shares rose sharply as investors rallied behind the oncology breakthrough.
Phase 3 INTerpath-001 Trial Profile:
• Trial Size: 1,137 patients with resected stage IIB-IV melanoma
• Primary Treatment: Intismeran autogene (mRNA-4157/V940) + Keytruda (pembrolizumab)
• Control Group: Keytruda alone (standard-of-care)
• Primary Endpoint: Recurrence-Free Survival (RFS) — MET
• Secondary Endpoint: Distant Metastasis-Free Survival (DMFS) — MET
• Significance: First positive Phase 3 trial for a personalized mRNA cancer vaccine
How Custom mRNA Cancer Vaccines Target Individual Tumors
Unlike traditional preventive vaccines, intismeran autogene is a therapeutic, tailor-made treatment manufactured specifically for each individual patient based on the unique genetic signature of their tumor.
Doctors analyze a sample of a patient’s excised tumor using advanced genomic sequencing to identify up to 34 unique mutational targets (neoantigens).
The Personalized mRNA Vaccine Mechanism
-
Genomic Sequencing: A biopsy of the patient’s tumor is sequenced to map its unique mutational signature.
-
mRNA Manufacturing: An individualized mRNA strand is synthesized carrying genetic instructions for the identified neoantigens.
-
Immune System Activation: Once administered, the mRNA instructs the patient’s cells to produce these specific neoantigens, training T-cells to identify and destroy remaining cancer cells.
-
Synergy with Keytruda: Keytruda disables the “brakes” on the immune system, allowing the vaccine-primed T-cells to launch a targeted attack against cancer cells.
Regulatory Path and Future Applications
Following these Phase 3 findings, Merck and Moderna plan to present detailed trial data at an upcoming international medical conference and engage with global regulatory authorities—including the U.S. Food and Drug Administration (FDA)—to apply for marketing approvals.
Researchers believe the success of personalized mRNA vaccines in melanoma could establish a blueprint for treating other solid tumors, including non-small cell lung cancer, pancreatic cancer, and renal cell carcinoma.
For further medical science updates and financial reporting, visit Reuters Health News.
Comment